Marinomed Biotech AG (CHIX:MARIV)

[p0]

Estim. target 127 € (135 USD) - Analysts at "Erste Group"
(that was before the P&G deal)

2002-05-04 - Analysts at "Erste Group" have lowered their price target for the shares of domestic Marinomed from 155.00 to 127.00 euros. The "buy" recommendation was confirmed by analyst Vladimira Urbankova.

Despite the company's lack of exposure to Russia/Ukraine markets and strong sales figures for 2021, Marinomed's share price has recently come under pressure, the latest report said. Taking into account recent news indicating delays in the launch of Budesolv on European markets, the revised price target is EUR 127.0, compared with the previous target of EUR 155.0, Erste experts added. However, an upside potential of more than 50 percent indicates that Marinomed's attractive investment story is far from being priced in, they added.